|1.29||-0.0100||-0.77%||Vol 149.41K||1Y Perf -91.48%|
|Oct 4th, 2023 16:00 DELAYED|
|- -||0.01 0.78%|
|Target Price||28.83||Analyst Rating||Moderate Buy 1.75|
|Potential %||2.13K||Finscreener Ranking||★★★★+ 56.41|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★ 56.61|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★+ 60.56|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★ — -|
|Price Range Ratio 52W %||0.10||Earnings Rating||Neutral|
|Market Cap||55.56M||Earnings Date||14th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||14th Nov 2023|
|Estimated EPS Next Report||-0.73|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||416.24K|
|Avg. Monthly Volume||430.57K|
|Avg. Quarterly Volume||548.29K|
Adicet Bio Inc. (NASDAQ: ACET) stock closed at 1.29 per share at the end of the most recent trading day (a -0.77% change compared to the prior day closing price) with a volume of 149.41K shares and market capitalization of 55.56M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. Adicet Bio Inc. CEO is Chen Schor.
The one-year performance of Adicet Bio Inc. stock is -91.48%, while year-to-date (YTD) performance is -85.57%. ACET stock has a five-year performance of -42.67%. Its 52-week range is between 1.27 and 21.87, which gives ACET stock a 52-week price range ratio of 0.10%
Adicet Bio Inc. currently has a PE ratio of -5.80, a price-to-book (PB) ratio of 1.13, a price-to-sale (PS) ratio of 5.98, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -19.48%, a ROC of -19.85% and a ROE of -22.22%. The company’s profit margin is -76.31%, its EBITDA margin is -176.60%, and its revenue ttm is $24.99 Million , which makes it $1.28 revenue per share.
Of the last four earnings reports from Adicet Bio Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.73 for the next earnings report. Adicet Bio Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for Adicet Bio Inc. is Moderate Buy (1.75), with a target price of $28.83, which is +2 134.88% compared to the current price. The earnings rating for Adicet Bio Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Adicet Bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of 123.00%.
Adicet Bio Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.36, ATR14 : 0.13, CCI20 : -130.15, Chaikin Money Flow : -0.48, MACD : -0.18, Money Flow Index : 35.88, ROC : -23.98, RSI : 27.08, STOCH (14,3) : 5.16, STOCH RSI : 0.00, UO : 30.08, Williams %R : -94.84), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Adicet Bio Inc. in the last 12-months were: Advisors LLC. Orbimed (Buy at a value of $1 828 750), Blake Aftab (Option Excercise at a value of $25 003), Blake Aftab (Sold 16 680 shares of value $302 905 ), Carl Gordon (Buy at a value of $1 828 750), Chen Schor (Sold 95 268 shares of value $1 839 448 ), Don Healey (Sold 10 467 shares of value $83 476 ), DUBIN STEVE (Buy at a value of $12 000), Healey Don (Sold 15 000 shares of value $117 841 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.